BOSTON — Nov. 13, 2015 — Global law firm Greenberg Traurig, LLP shareholders Robert L. Grossman and David J. Dykeman will present at the Therapeutic Area Partnerships (TAP) 2015 Conference, Nov. 18-20, 2015, at the Hilton Back Bay in Boston. On Wednesday, Nov. 18, from 3:30 p.m. – 6:30 p.m., Grossman and Dykeman will serve as panelists for the pre-conference workshop, “Essential Dimensions in in Partnering: Goal - Strategy - Target Selection - Doing the Deal.” This session will provide a comprehensive framework for the deal-making process in the biotechnology industry. Topics include:
- Overview, trends, problems, and strategic relevance of different deal types, such as licensing deals, partnering contracts, asset deals, and company sales;
- Best practices in deal preparation (strategy, asset valuation, target search, and selection);
- Best practices in deal initiation & closing (term sheet, due diligence, typical deal terms, and traps to avoid); and
- Case studies on common pitfalls and discussion of individual challenges of participants present.
According to its website, TAP brings together decision-makers to assess the most promising drug programs available for partnering in neuroscience, inflammatory/autoimmune, oncology, cardiovascular/metabolic, infectious diseases, and advanced therapies (including regenerative medicine, rare diseases, gene therapy, cell therapy, and other high-value and niche areas). Respected independent experts rigorously review projects available for partnering and select the top 10 projects in each therapeutic area based on the likelihood of their success as future products. Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders.
Based in Greenberg Traurig’s Miami office, Grossman is a shareholder in the firm’s Securities, M&A, and Corporate practices as well as the Global Life Sciences & Medical Technology Group, and is co-chair of the Global Israel Practice. With wide-ranging experience taking companies public, acquiring and selling companies, and as a business advisor, Grossman has represented a diverse collection of public and private companies, including companies in the medical device, pharmaceutical, biotechnology, health care, energy and natural resources, technology and software, and communications industries.
Dykeman is a patent attorney, co-chair of Greenberg Traurig’s Global Life Sciences & Medical Technology Group, and co-chair of the firm’s Intellectual Property (IP) Group in Boston. With nearly 20 years of experience in patents, intellectual property, and licensing, Dykeman focuses his practice on securing strategic worldwide intellectual property protection and related business strategy for high-tech clients, with particular expertise in life sciences, medical devices, biotechnology, and healthcare IT. Dykeman is the founding co-chair of the American Bar Association’s (ABA) Medical Devices Committee and serves on the Editorial Advisory Board of Medical Device + Diagnostic Industry (MD+DI) Magazine.
An author of over 45 articles and a speaker at over 40 conferences on medical devices and life sciences intellectual property, Dykeman was honored as a “Life Science Star” by LMG Life Sciences and was named one of the Top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine.